Clinical Trial Update: Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluating CAT-2003 for familial chylomicronemia syndrome and related lipid disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome
• Hyperlipoproteinemia Type
• Hypertriglyceridemia

Drugs mentioned

• CAT-2003

Snippet

Sponsor: Catabasis Pharmaceuticals | Conditions: Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I | Phase 2 | Status: COMPLETED